TSAA-291の前立腺肥大症に対する使用経験

Abstract

Twenty-eight patients with benign prostatic hypertrophy ranging in age from 61 to 84 were treated with TSAA-291 for 12 weeks. 1. Seventeen patients received TSAA-291 in a dose of 200 mg once a week. The clinical response was favorable in 10 patients (59%): dysuria, nycturia, residual urine and urethrography being improved in 60~ 70% of the patients. 2. Eleven patients recieved TSAA-291 in a dose of 400 mg once a week or 200 mg twice a week. The responce was good in 7 patients (64%). Improvement of the above four clinical symptoms was the same or greater than that with the dose of200 mg a week. 3. No severe side-effects were observed in any case. Two patients complained of pain and burning at the injection sites.